



## Acquisitions of own shares and Disposals of own shares

Brussels (Belgium), 10 April 2020 – 20:00 (CEST) – regulated information

### Acquisitions of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV (“UCB” or the “Company”) (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2020.

Under this program, UCB has requested a financial intermediary to repurchase up to 1.2 million UCB shares on its behalf under the terms of an initial discretionary mandate agreement with validity until 15 June 2020, effective as from 25 March 2020, to cover current and future obligations under UCB’s Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2020, UCB repurchased 50 010 UCB shares on Euronext Brussels in the period from 3 April 2020 up to and including 9 April 2020, as follows:

| Date of repurchase | Number of shares | Average Price Paid | Total          | Lowest Price Paid | Highest Price Paid |
|--------------------|------------------|--------------------|----------------|-------------------|--------------------|
| 03 April 2020      | 9,186            | € 80.07            | € 735,552.42   | € 78.20           | € 80.90            |
| 06 April 2020      | 6,371            | € 80.65            | € 513,817.33   | € 80.04           | € 81.78            |
| 07 April 2020      | 6,450            | € 80.87            | € 521,592.80   | € 80.38           | € 82.00            |
| 08 April 2020      | 19,766           | € 79.94            | € 1,580,056.48 | € 79.50           | € 81.50            |
| 09 April 2020      | 8,237            | € 80.20            | € 660,628.82   | € 79.60           | € 81.50            |

### Disposals of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

| Date of transaction | Time     | LTI Plan               | Number of disposed UCB shares | Price   |
|---------------------|----------|------------------------|-------------------------------|---------|
| 03 April 2020       | 11:51:02 | Stock Option Plan 2017 | 2,500                         | € 70.26 |
| 03 April 2020       | 16:37:18 | Stock Option Plan 2011 | 5,000                         | € 26.72 |
| 06 April 2020       | 09:01:31 | Stock Option Plan 2011 | 400                           | € 26.72 |
| 06 April 2020       | 11:06:36 | Stock Option Plan 2012 | 100                           | € 32.36 |
| 06 April 2020       | 11:13:52 | Stock Option Plan 2012 | 400                           | € 32.36 |
| 07 April 2020       | 09:02:30 | Stock Option Plan 2016 | 10,219                        | € 67.24 |
| 07 April 2020       | 09:05:23 | Stock Option Plan 2017 | 1,851                         | € 70.26 |
| 07 April 2020       | 11:33:20 | Stock Option Plan 2016 | 1,022                         | € 67.24 |
| 07 April 2020       | 15:07:40 | Stock Option Plan 2012 | 1,000                         | € 32.36 |
| 08 April 2020       | 09:00:01 | Stock Option Plan 2011 | 5,000                         | € 26.72 |
| 09 April 2020       | 09:13:42 | Stock Option Plan 2013 | 4,995                         | € 48.69 |

This press release is available on UCB SA/NV's website via the following [link](#).

### Investor Relations

Antje Witte,  
Investor Relations, UCB  
T +32 2 559 94 14,  
[antje.witte@ucb.com](mailto:antje.witte@ucb.com)

Isabelle Ghellynck,  
Investor Relations, UCB  
T +32 2 559 95 88,  
[isabelle.ghellynck@ucb.com](mailto:isabelle.ghellynck@ucb.com)

### About UCB

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news